拉米夫定抗病毒治疗的乙型肝炎患者血清乙肝大蛋白和乙肝病毒DNA监测分析  

The monitoring analysis of serum HBV-LP and HBV-DNA in lamivudine antiviral therapy for patients with hepatitis B

作　　者：盛江来[1] 黄海军[2] 

机构地区：[1]浙江安吉县人民医院,浙江安吉313300 [2]浙江大学医学院附属第一医院,杭州310003

出　　处：《中国卫生检验杂志》2010年第9期2240-2241,2244,共3页Chinese Journal of Health Laboratory Technology

摘　　要：目的：监测拉米夫定抗病毒治疗的乙型肝炎患者血清中的乙型肝炎病毒大蛋白（HBV-LP）和乙型肝炎病毒DNA（HBV-DNA）载量,探讨拉米夫定治疗过程中HBV-LP与HBV-DNA的关系,观察乙型肝炎病毒大蛋白用于评估拉米夫定抗病毒治疗效果的应用效果。方法：采用酶联免疫吸附试验（ELISA）的方法检测HBV-LP;采用荧光定量PCR方法对HBV-DNA进行检测。结果：47例患者接受拉米夫定抗病毒治疗12个月后HBV-DNA、HBV-LP两个检测指标阴转率无明显差别,HBV-LP转阴时间比HBV-DNA晚3-6个月;抗病毒治疗过程中,HBV-DNA和HBV-LP均呈下降趋势有较高的相关性,r=0.81,P〈0.01。结论：拉米夫定抗病毒治疗过程中动态检测乙型肝炎病毒大蛋白可用于评估抗病毒治疗效果。Objective：To monitor the serum Hepatitis B virus large surface protein（HBV-LP） and HBV-DNA copies in lamivudine antiviral therapy for patients with hepatatitis B,exploring the significance of HBV-LP in assessing the effect of antiviral therapy with lamivudine.Methods： HBV-LP was measured by enzyme-liked immunosorbent assay（ELISA） and serum HBV-DNA level was quantitatively detected by real-time polymerase chain reaction（PCR）.Results： The 47 patients were treated with lamivudine therapy and 12 months later the negative rate of the HBV-DNA was not significantly different with the HBV-LP.But the HBV-LP turned negative 3 to 6 moths earlier than HBV-DNA.During the antiviral treatmenting,the decline of the HBV-DNA was positively correlated with HBV-LP（r=0.81,P〈0.01）.Conclusion： HBV-LP may serve as a reliable marker which can reflect the effectiveness during the antiviral lamivudine therapy.

关 键 词：乙型肝炎病毒大蛋白 乙型肝炎病毒DNA 肝炎病毒 乙型 抗病毒治疗 

分 类 号：R512.62[医药卫生—内科学]